CD274 and tarsal-carpal coalition syndrome: Supported by phase III second line and single arm phase II first line data, atezolizumab, avelumab (anti-PD-L1), pembrolizumab and nivolumab (anti-PD-1), are approved for use in Europe in patients with advanced TCC [8–12].